Medroxyprogesterone acetate impairs human dendritic cell activation and function.

ABSTRACT:

Study question

Does medroxyprogesterone acetate (MPA) impair human dendritic cell (DC) activation and function?

Summary answer

In vitro MPA treatment suppressed expression of CD40 and CD80 by human primary DCs responding to Toll-like receptor 3 (TLR3) agonist stimulation (i.e. DC activation). Moreover, this MPA-mediated decrease in CD40 expression impaired DC capacity to stimulate T cell proliferation (i.e. DC function).

What is known already

MPA is the active molecule in Depo-Provera(®) (DMPA), a commonly used injectable hormonal contraceptive (HC). Although DMPA treatment of mice prior to viral mucosal tissue infection impaired the capacity of DCs to up-regulate CD40 and CD80 and prime virus-specific T cell proliferation, neither DC activation marker expression nor

SUBMITTER: Quispe Calla NE 

PROVIDER: S-EPMC4481667 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature